<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963051</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00071007</org_study_id>
    <nct_id>NCT02963051</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer</brief_title>
  <official_title>A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel George, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Give 1 For Dad Campaign</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The V Foundation for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peter Michael Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and optimal dosing of intravenous copper&#xD;
      chloride and disulfiram in men with metastatic castrate-resistant prostate cancer (CRPC).&#xD;
      Eligible men will have neuroendocrine prostate cancer (NEPC), adenocarcinoma CRPC with&#xD;
      non-liver/peritoneal metastases (lymph nodes, bone, or lung) or adenocarcinoma CRPC with&#xD;
      liver and/or peritoneal metastases. Subjects will receive three doses of intravenous copper&#xD;
      chloride and take disulfiram and oral copper gluconate until disease progression (up to two&#xD;
      years). Subjects will also undergo a PET scan with radioactive copper 64 to measure the&#xD;
      levels of copper in their tumor. The central hypotheses of this project are that (a) copper&#xD;
      chloride and disulfiram are safe to give together and that (b) the combination of disulfiram&#xD;
      with copper will have efficacy for both mCRPC and NEPC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped due to lack of efficacy.&#xD;
  </why_stopped>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Actual">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Safety (NCI CTC v4.0) and tolerability of IV CuCl2 and DSF in men with mCRPC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median radiographic progression free survival (PFS)</measure>
    <time_frame>Every 12 weeks, up to 2 years</time_frame>
    <description>Radiographic PFS based on PCWG3 criteria or based on the onset of a skeletal related event. Imaging obtained every 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of 64-Copper uptake by the tumor</measure>
    <time_frame>Baseline</time_frame>
    <description>64-Copper PET imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PSA</measure>
    <time_frame>Every 4 weeks, up to 2 years</time_frame>
    <description>PSA response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA nadir</measure>
    <time_frame>Every 4 weeks, up to 2 years</time_frame>
    <description>Time to PSA nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>Every 4 weeks, up to 2 years</time_frame>
    <description>Time to PSA progression</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Neuroendocrine prostate cancer (NEPC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with neuroendocrine prostate cancer (NEPC)&#xD;
Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adenocarcinoma CRPC with non-liver/peritoneal metastases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with adenocarcinoma CRPC with non-liver/peritoneal metastases (lymph nodes, bone, or lung)&#xD;
Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adenocarcinoma CRPC with liver and/or peritoneal mets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with adenocarcinoma CRPC with liver and/or peritoneal metastases&#xD;
Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copper</intervention_name>
    <description>1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15</description>
    <arm_group_label>Adenocarcinoma CRPC with liver and/or peritoneal mets</arm_group_label>
    <arm_group_label>Adenocarcinoma CRPC with non-liver/peritoneal metastases</arm_group_label>
    <arm_group_label>Neuroendocrine prostate cancer (NEPC)</arm_group_label>
    <other_name>Copper chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Disulfiram</intervention_name>
    <description>80 mg three times a day&#xD;
Source of disulfiram: Cantex Pharmaceuticals</description>
    <arm_group_label>Adenocarcinoma CRPC with liver and/or peritoneal mets</arm_group_label>
    <arm_group_label>Adenocarcinoma CRPC with non-liver/peritoneal metastases</arm_group_label>
    <arm_group_label>Neuroendocrine prostate cancer (NEPC)</arm_group_label>
    <other_name>Anatabuse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copper gluconate</intervention_name>
    <description>1.5 mg three times a day&#xD;
Source of copper gluconate: Cantex Pharmaceuticals</description>
    <arm_group_label>Adenocarcinoma CRPC with liver and/or peritoneal mets</arm_group_label>
    <arm_group_label>Adenocarcinoma CRPC with non-liver/peritoneal metastases</arm_group_label>
    <arm_group_label>Neuroendocrine prostate cancer (NEPC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Karnofsky performance status ≥ 70&#xD;
&#xD;
          3. Life expectancy of ≥ 12 weeks as determined by treating investigator&#xD;
&#xD;
          4. Adequate laboratory parameters&#xD;
&#xD;
               -  Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 80 x&#xD;
                  109/L, Hb&gt;9 g/dL&#xD;
&#xD;
               -  AST/SGOT and ALT/SGPT ≤ 2.5 x Institutional Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x Institutional ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x Institutional ULN or 24-hour clearance ≥ 50 mL/min&#xD;
&#xD;
          5. Histologically confirmed diagnosis of prostate cancer. Histologic variants of prostate&#xD;
             cancer, including neuroendocrine features and small cell carcinoma of the prostate are&#xD;
             included.If neuroendocrine prostate cancer is not biopsy proven, clinical evidence of&#xD;
             neuroendocrine prostate cancer is acceptable for stratification into group A.&#xD;
&#xD;
          6. Radiographic evidence of metastatic disease.&#xD;
&#xD;
          7. Ongoing ADT using an LHRH agonist (e.g. leuprolide, goserelin) or antagonist (e.g.&#xD;
             degarelix) must continue on therapy unless prior bilateral orchiectomy has been&#xD;
             performed. OR Screening serum testosterone must be &lt;50 ng/dl.&#xD;
&#xD;
          8. Evidence of disease progression on ADT as evidenced by one of the following:&#xD;
&#xD;
               -  2 consecutive PSA levels 50% or greater above the PSA nadir achieved on ADT and&#xD;
                  separated at least 1 week apart, OR&#xD;
&#xD;
               -  CT or MRI based evidence of disease progression (soft tissue, nodal or visceral&#xD;
                  disease progression) according to PCWG3 criteria or RECIST 1.1 criteria, or at&#xD;
                  least 1 new bone scan lesion as compared to the most immediate prior radiologic&#xD;
                  studies, OR&#xD;
&#xD;
               -  Absolute rise in PSA of 2.0ng/mL or greater, minimum 2 consecutive rising PSA&#xD;
                  levels with an interval of ≥ 1 week between each PSA level&#xD;
&#xD;
          9. A minimum of 2 weeks elapsed off of antiandrogen therapy prior to registration (i.e.&#xD;
             flutamide, nilutamide, and bicalutamide) without evidence of an anti-androgen&#xD;
             withdrawal response. An anti-androgen withdrawal response is a PSA level at 2 weeks&#xD;
             (or more) off of anti-androgen equal or higher than PSA level when anti-androgen&#xD;
             therapy stopped.&#xD;
&#xD;
         10. For subjects in Groups B or C, previous use of at least one androgen pathway inhibitor&#xD;
             (either abiraterone acetate or enzalutamide) for metastatic CRPC&#xD;
&#xD;
         11. For subjects in Group A with NEPC, previous use of at least one platinum-containing&#xD;
             chemotherapy regimen.&#xD;
&#xD;
         12. A minimum of 2 weeks off of enzalutamide or abiraterone if applicable, prior to&#xD;
             registration.&#xD;
&#xD;
         13. A minimum of 4 weeks from prior chemotherapy, including but not limited to, docetaxel,&#xD;
             cabazitaxel, mitoxantrone, carboplatinum, cisplatin, or estramustine; if applicable,&#xD;
             prior to registration.&#xD;
&#xD;
         14. A minimum of 4 weeks from any major surgery prior to registration.&#xD;
&#xD;
         15. Ability to swallow, retain, and absorb oral medication.&#xD;
&#xD;
         16. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
         17. Willingness to abstain from alcohol or any alcohol-containing fluids for the duration&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Symptomatic subjects who accept treatment with approved palliative or life-prolonging&#xD;
             systemic therapies, including docetaxel and cabazitaxel chemotherapy. (Note: subjects&#xD;
             who refuse chemotherapy or are not symptomatic or in immediate need for standard&#xD;
             systemic therapies may be included.)&#xD;
&#xD;
          2. Known history of Wilson's disease or a copper deficiency.&#xD;
&#xD;
          3. Uncontrolled hypertension (systolic BP &gt;160 mmHg or diastolic BP &gt; 95 mmHg) or other&#xD;
             medical condition that could jeopardize the assessment of toxicity on study.&#xD;
&#xD;
          4. Active or symptomatic viral hepatitis or chronic liver disease.&#xD;
&#xD;
          5. Known history of Hepatitis B Virus (HBV) or Hepatitis C (HCV) infection.&#xD;
&#xD;
          6. Clinically significant heart disease as evidenced by myocardial infarction, or&#xD;
             arterial thrombotic events in the past 6 months, severe or unstable angina, or New&#xD;
             York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction&#xD;
             measurement of &lt; 50% at baseline.&#xD;
&#xD;
          7. Symptomatic atrial fibrillation or other cardiac arrhythmia for which the therapy is&#xD;
             not stable or requiring changes in therapy within 1 month of treatment initiation.&#xD;
             Atrial fibrillation or other cardiac arrhythmia which is clinically stable on stable&#xD;
             therapy is allowed.&#xD;
&#xD;
          8. Corrected QT interval calculated by the Bazett formula (QTcB) &gt;480 msec.&#xD;
&#xD;
          9. Other malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of death&#xD;
             within 24 months.&#xD;
&#xD;
         10. Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1.&#xD;
&#xD;
         11. Any condition which, in the opinion of the investigator, would preclude participation&#xD;
             in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Daniel George, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>metastatic castrate-resistant prostate cancer (mCRPC)</keyword>
  <keyword>neuroendocrine prostate cancer (NEPC)</keyword>
  <keyword>adenocarcinoma castrate-resistant prostate cancer (CRPC)</keyword>
  <keyword>Copper</keyword>
  <keyword>Disulfiram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
    <mesh_term>Disulfiram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

